SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Ping An Biomedical Co., Ltd.
Date: Feb. 20, 2026 · CIK: 0001897532 · Accession: 0000000000-26-001742

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293481

Date
February 20, 2026
Author
Division of
Form
UPLOAD
Company
Ping An Biomedical Co., Ltd.

Letter

Re: Ping An Biomedical Co., Ltd. Registration Statement on Form F-1 Filed February 13, 2026 File No. 333-293481 Dear Pijun Liu:

February 20, 2026

Pijun Liu Chief Executive Officer Ping An Biomedical Co., Ltd. 22/F, China United Plaza 1002-1008, Tai Nan West Street Cheung Sha Wan, Kowloon Hong Kong

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Erin Donahue at 202-551-6063 with any questions.

Sincerely,
Division of
Corporation Finance
Office of
Manufacturing

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           February 20, 2026

Pijun Liu
Chief Executive Officer
Ping An Biomedical Co., Ltd.
22/F, China United Plaza
1002-1008, Tai Nan West Street
Cheung Sha Wan, Kowloon
Hong Kong

       Re: Ping An Biomedical Co., Ltd.
           Registration Statement on Form F-1
           Filed February 13, 2026
           File No. 333-293481
Dear Pijun Liu:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Erin Donahue at 202-551-6063 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of
Manufacturing
</TEXT>
</DOCUMENT>